152 related articles for article (PubMed ID: 28364247)
1. Intracerebroventricular Delivery in Mice for Motor Neuron Diseases.
Nizzardo M; Rizzuti M
Methods Mol Biol; 2017; 1565():229-239. PubMed ID: 28364247
[TBL] [Abstract][Full Text] [Related]
2. Effect of combined systemic and local morpholino treatment on the spinal muscular atrophy Δ7 mouse model phenotype.
Nizzardo M; Simone C; Salani S; Ruepp MD; Rizzo F; Ruggieri M; Zanetta C; Brajkovic S; Moulton HM; Müehlemann O; Bresolin N; Comi GP; Corti S
Clin Ther; 2014 Mar; 36(3):340-56.e5. PubMed ID: 24636820
[TBL] [Abstract][Full Text] [Related]
3. The Overexpression of TDP-43 Protein in the Neuron and Oligodendrocyte Cells Causes the Progressive Motor Neuron Degeneration in the SOD1 G93A Transgenic Mouse Model of Amyotrophic Lateral Sclerosis.
Lu Y; Tang C; Zhu L; Li J; Liang H; Zhang J; Xu R
Int J Biol Sci; 2016; 12(9):1140-9. PubMed ID: 27570488
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation.
Peviani M; Salvaneschi E; Bontempi L; Petese A; Manzo A; Rossi D; Salmona M; Collina S; Bigini P; Curti D
Neurobiol Dis; 2014 Feb; 62():218-32. PubMed ID: 24141020
[TBL] [Abstract][Full Text] [Related]
5. Systemic and ICV Injections of Antisense Oligos into SMA Mice and Evaluation.
Aslesh T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():455-465. PubMed ID: 30171559
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 Deficiency Does Not Affect Motor Neuron Disease Caused by Superoxide Dismutase 1 Mutation.
Han Y; Ripley B; Serada S; Naka T; Fujimoto M
PLoS One; 2016; 11(4):e0153399. PubMed ID: 27070121
[TBL] [Abstract][Full Text] [Related]
7. Gene Therapy for ALS-A Perspective.
Cappella M; Ciotti C; Cohen-Tannoudji M; Biferi MG
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500113
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy for amyotrophic lateral sclerosis and other motor neuron diseases.
Alisky JM; Davidson BL
Hum Gene Ther; 2000 Nov; 11(17):2315-29. PubMed ID: 11096437
[TBL] [Abstract][Full Text] [Related]
9. Multiple intracerebroventricular injections of human umbilical cord mesenchymal stem cells delay motor neurons loss but not disease progression of SOD1G93A mice.
Sironi F; Vallarola A; Violatto MB; Talamini L; Freschi M; De Gioia R; Capelli C; Agostini A; Moscatelli D; Tortarolo M; Bigini P; Introna M; Bendotti C
Stem Cell Res; 2017 Dec; 25():166-178. PubMed ID: 29154076
[TBL] [Abstract][Full Text] [Related]
10. VEGF at the neurovascular interface: therapeutic implications for motor neuron disease.
Lambrechts D; Carmeliet P
Biochim Biophys Acta; 2006; 1762(11-12):1109-21. PubMed ID: 16784838
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis.
Angelov DN; Waibel S; Guntinas-Lichius O; Lenzen M; Neiss WF; Tomov TL; Yoles E; Kipnis J; Schori H; Reuter A; Ludolph A; Schwartz M
Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4790-5. PubMed ID: 12668759
[TBL] [Abstract][Full Text] [Related]
12. Spinal muscular atrophy phenotype is ameliorated in human motor neurons by SMN increase via different novel RNA therapeutic approaches.
Nizzardo M; Simone C; Dametti S; Salani S; Ulzi G; Pagliarani S; Rizzo F; Frattini E; Pagani F; Bresolin N; Comi G; Corti S
Sci Rep; 2015 Jun; 5():11746. PubMed ID: 26123042
[TBL] [Abstract][Full Text] [Related]
13. Cellular therapies in motor neuron diseases.
Nayak MS; Kim YS; Goldman M; Keirstead HS; Kerr DA
Biochim Biophys Acta; 2006; 1762(11-12):1128-38. PubMed ID: 16872810
[TBL] [Abstract][Full Text] [Related]
14. Cross-disease comparison of amyotrophic lateral sclerosis and spinal muscular atrophy reveals conservation of selective vulnerability but differential neuromuscular junction pathology.
Comley LH; Nijssen J; Frost-Nylen J; Hedlund E
J Comp Neurol; 2016 May; 524(7):1424-42. PubMed ID: 26502195
[TBL] [Abstract][Full Text] [Related]
15. [Gene Therapies in Motor Neuron Diseases ALS and SMA].
Günther R
Fortschr Neurol Psychiatr; 2023 Apr; 91(4):153-163. PubMed ID: 36822211
[TBL] [Abstract][Full Text] [Related]
16. Transcriptomic indices of fast and slow disease progression in two mouse models of amyotrophic lateral sclerosis.
Nardo G; Iennaco R; Fusi N; Heath PR; Marino M; Trolese MC; Ferraiuolo L; Lawrence N; Shaw PJ; Bendotti C
Brain; 2013 Nov; 136(Pt 11):3305-32. PubMed ID: 24065725
[TBL] [Abstract][Full Text] [Related]
17. Antisense Oligonucleotides (ASOs) in Motor Neuron Diseases: A Road to Cure in Light and Shade.
Cantara S; Simoncelli G; Ricci C
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732027
[TBL] [Abstract][Full Text] [Related]
18. Comparison of independent screens on differentially vulnerable motor neurons reveals alpha-synuclein as a common modifier in motor neuron diseases.
Kline RA; Kaifer KA; Osman EY; Carella F; Tiberi A; Ross J; Pennetta G; Lorson CL; Murray LM
PLoS Genet; 2017 Mar; 13(3):e1006680. PubMed ID: 28362802
[TBL] [Abstract][Full Text] [Related]
19. Disruption of the astrocytic TNFR1-GDNF axis accelerates motor neuron degeneration and disease progression in amyotrophic lateral sclerosis.
Brambilla L; Guidotti G; Martorana F; Iyer AM; Aronica E; Valori CF; Rossi D
Hum Mol Genet; 2016 Jul; 25(14):3080-3095. PubMed ID: 27288458
[TBL] [Abstract][Full Text] [Related]
20. [Experimental approach to the gene therapy of motor neuron disease with the use of genes hypoxia-inducible factors].
Ismailov ShM; Barykova IuA; Shmarov MM; Tarantul VZ; Barskov IV; Kucherianu VG; Brylev LV; Logunov DIu; Tutykhina IL; Bocharov EV; Zakharova MN; Naroditskiĭ BS; Illarioshkin SN
Genetika; 2014 May; 50(5):591-601. PubMed ID: 25715475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
